A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndromeAzra Raza, Mikkael A. Sekeres, Naomi Galili et al.|Cancer|2011Cited by 44
Novel Flt-3/KDR inhibitor is effective against activated Flt-3 and is cytotoxic against Flt-3-driven leukemias in vitro and in vivoStephen C. Beck, Laura Sepp‐Lorenzino, Bin Shi et al.|Cancer Research|2004Cited by 0